LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly and Company LLY has seen unparalleled success with tirzepatide ... received approvals for several new drugs and witnessed pipeline and regulatory success. Other than Mounjaro and ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

Analysts are particularly optimistic about the demand for tirzepatide ... What potential does Eli Lilly's pipeline, particularly orforglipron, have for driving future growth?

Eli Lilly has thinned its pipeline in two critical therapeutic ... At one time, the Big Pharma was advancing a DACRA alongside tirzepatide, the active ingredient in Mounjaro and Zepbound, but ...

Eli Lilly and Company reported strong ... I suggested that too much was expected of its new product pipeline, featuring donanemab and tirzepatide. Yet, here we are today with Lilly challenging ...